BSH/ISH 2016 | SPIRIT2 trial on dasatinib for AML – safety and side effect management
Stephen O’Brien
• 18 Apr 2016
Stephen O’Brien, PhD, MBChB, FRCP, FRCPath from Newcastle University, Newcastle, UK, provides an overview of his talk on the SPIRIT2 trial in acute myeloid leukemia (AML) held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. SPIRIT2 (NCT01460693) is the largest Phase III randomized trial comparing imatinib and dasatinib and according to Prof O’Brien, dasatinib had a significantly higher rate of molecular response compared to imatinib. There is, however, no difference in overall survival (OS). Prof O’Brien further discusses the safety data and some case studies on how to manage pleural effusions he presented.
